Bayer’s Stivarga patent targeted in IPR petition

04-08-2016

Bayer’s Stivarga patent targeted in IPR petition

Feng Yu / Shutterstock.com

Fustibal, a targeted therapeutics biotechnology start-up, has filed an inter partes review (IPR) petition challenging a patent owned by German pharmaceutical company Bayer.


Bayer, Fustibal, Stivarga, PTAB, patent, IPR, inter partes review

LSIPR